Maitalon 30 (Drospirenone, Ethinylestradiol)

Drospirenone acts as a progestogen, while ethinylestradiol is an estrogen. Together they inhibit the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. The progestogenic component also thickens cervical mucus, and the estrogenic component stabilises the endometrium, reducing the chance of fertilisation and implantation.

The dosing regimen for Maitalon 30 is determined by the prescribing healthcare professional. Typically, the product is taken once daily for a defined cycle, but the exact number of tablets, timing and any break periods are set by the prescriber based on individual patient needs and clinical guidelines.

Maitalon 30 is not intended for use during pregnancy; it should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, most combined oral contraceptives are considered compatible with lactation, but clinicians should evaluate the risk‑benefit profile for each patient and discuss alternatives if concerns arise.

To order Maitalon 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Maitalon 30 contains drospirenone, a progestogen with anti‑androgenic and antimineralocorticoid properties, which may offer benefits such as reduced water retention and acne improvement compared with some older progestins. Efficacy in preventing pregnancy is comparable to other COCs, but the side‑effect profile can differ, making individual patient factors important when selecting a formulation.

Maitalon 30 tablets should be stored at room temperature below 25 °C, in their original blister pack, and protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Maitalon 30 is taken orally, usually once each day at the same time, with or without food. Patients should follow the prescriber's instructions regarding the start of the first tablet, any placebo days, and what to do if a dose is missed, to maintain contraceptive effectiveness.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction and severe hypertension. Women should seek immediate medical attention if they experience sudden leg pain, chest discomfort, shortness of breath, severe headache, visual changes or unexplained swelling, as these may signal a serious clot‑related event.

Maitalon 30 is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking strong CYP3A4‑inducing medications without appropriate medical supervision.